CGC vs. CRON, PRTA, AVBP, ORGO, CRMD, CVAC, GHRS, IMNM, NUVB, and ABUS
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Cronos Group (CRON), Prothena (PRTA), ArriVent BioPharma (AVBP), Organogenesis (ORGO), CorMedix (CRMD), CureVac (CVAC), GH Research (GHRS), Immunome (IMNM), Nuvation Bio (NUVB), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.
Canopy Growth vs.
Canopy Growth (NASDAQ:CGC) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.
In the previous week, Cronos Group had 3 more articles in the media than Canopy Growth. MarketBeat recorded 6 mentions for Cronos Group and 3 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 1.17 beat Cronos Group's score of 0.35 indicating that Canopy Growth is being referred to more favorably in the media.
Canopy Growth has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 1.3% of Canopy Growth shares are held by insiders. Comparatively, 6.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Canopy Growth currently has a consensus price target of $2.00, suggesting a potential upside of 102.92%. Cronos Group has a consensus price target of $3.00, suggesting a potential upside of 67.60%. Given Canopy Growth's higher probable upside, research analysts plainly believe Canopy Growth is more favorable than Cronos Group.
Cronos Group received 444 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 19.23% of users gave Canopy Growth an outperform vote.
Cronos Group has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.
Cronos Group has a net margin of -42.65% compared to Canopy Growth's net margin of -156.98%. Cronos Group's return on equity of -2.56% beat Canopy Growth's return on equity.
Summary
Cronos Group beats Canopy Growth on 12 of the 16 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
This page (NASDAQ:CGC) was last updated on 3/31/2025 by MarketBeat.com Staff
